Jonathan L. Wright
YOU?
Author Swipe
View article: High-Pressure Synthesis of the First Thermodynamically Stable Silver Nitride, AgN <sub>5</sub>
High-Pressure Synthesis of the First Thermodynamically Stable Silver Nitride, AgN <sub>5</sub> Open
View article: Twelve-Month Results From the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-Grade Non–Muscle-Invasive Bladder Cancer
Twelve-Month Results From the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-Grade Non–Muscle-Invasive Bladder Cancer Open
PURPOSE To compare patient-reported and clinical outcomes between radical cystectomy (RC) and bladder-sparing therapy (BST) in patients with recurrent high-grade non–muscle-invasive bladder cancer (NMIBC). PATIENTS AND METHODS This pragmat…
View article: Supplementary Table from Methylation Subtypes of Primary Prostate Cancer Predict Poor Prognosis
Supplementary Table from Methylation Subtypes of Primary Prostate Cancer Predict Poor Prognosis Open
Supplementary Table from Methylation Subtypes of Primary Prostate Cancer Predict Poor Prognosis
View article: Data from Methylation Subtypes of Primary Prostate Cancer Predict Poor Prognosis
Data from Methylation Subtypes of Primary Prostate Cancer Predict Poor Prognosis Open
Background:Patients with prostate cancer experience heterogeneous outcomes after radical prostatectomy. Genomic studies including The Cancer Genome Atlas (TCGA) have reported molecular signatures of prostate cancer, but few studies have as…
View article: Supplementary Table from Methylation Subtypes of Primary Prostate Cancer Predict Poor Prognosis
Supplementary Table from Methylation Subtypes of Primary Prostate Cancer Predict Poor Prognosis Open
Supplementary Table from Methylation Subtypes of Primary Prostate Cancer Predict Poor Prognosis
View article: Supplementary Figure from Methylation Subtypes of Primary Prostate Cancer Predict Poor Prognosis
Supplementary Figure from Methylation Subtypes of Primary Prostate Cancer Predict Poor Prognosis Open
Supplementary Figure from Methylation Subtypes of Primary Prostate Cancer Predict Poor Prognosis
View article: Supplementary Information from Prostate Cancer Risk Stratification via Nondestructive 3D Pathology with Deep Learning–Assisted Gland Analysis
Supplementary Information from Prostate Cancer Risk Stratification via Nondestructive 3D Pathology with Deep Learning–Assisted Gland Analysis Open
Supplementary methods, notes, figures, tables, video captions, and references
View article: Supplementary Information from Prostate Cancer Risk Stratification via Nondestructive 3D Pathology with Deep Learning–Assisted Gland Analysis
Supplementary Information from Prostate Cancer Risk Stratification via Nondestructive 3D Pathology with Deep Learning–Assisted Gland Analysis Open
Supplementary methods, notes, figures, tables, video captions, and references
View article: Supplementary Information from Prostate Cancer Risk Stratification via Nondestructive 3D Pathology with Deep Learning–Assisted Gland Analysis
Supplementary Information from Prostate Cancer Risk Stratification via Nondestructive 3D Pathology with Deep Learning–Assisted Gland Analysis Open
Supplementary methods, notes, figures, tables, video captions, and references
View article: Supplementary Information from Prostate Cancer Risk Stratification via Nondestructive 3D Pathology with Deep Learning–Assisted Gland Analysis
Supplementary Information from Prostate Cancer Risk Stratification via Nondestructive 3D Pathology with Deep Learning–Assisted Gland Analysis Open
Supplementary methods, notes, figures, tables, video captions, and references
View article: Fuel-poverty-constrained retrofit optimization: A socio-technical approach to decarbonising the UK building stock
Fuel-poverty-constrained retrofit optimization: A socio-technical approach to decarbonising the UK building stock Open
View article: 864 Delineating the role of growth differentiation Factor 15 (GDF-15) in advanced bladder and upper tract urinary cancers (BC): university of Washington rapid autopsy program (UW-RAP) cohort
864 Delineating the role of growth differentiation Factor 15 (GDF-15) in advanced bladder and upper tract urinary cancers (BC): university of Washington rapid autopsy program (UW-RAP) cohort Open
View article: Figure S1 from Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies
Figure S1 from Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies Open
Supplemental figure 1
View article: Table 1 from Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies
Table 1 from Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies Open
Estimated probabilities of HER2 expression conditional on an index sample
View article: Figure S2 from Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies
Figure S2 from Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies Open
Supplemental figure 2
View article: Supplementary Table 2 from Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies
Supplementary Table 2 from Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies Open
UC cohort supplemental table
View article: Data from Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies
Data from Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies Open
HER2 is an oncogenic driver in multiple cancers and a predictive biomarker for HER2-targeted therapies. Although HER2-directed therapies like fam-trastuzumab deruxtecan are approved for HER2-positive breast and other solid tumors, the land…
View article: Figure 3 from Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies
Figure 3 from Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies Open
A and B, Box plots indicating the relationship between HER2 score with protein expression of key cell surface antigens as measured by IHC in (A) prostate cancer and (B) urothelial cancer.
View article: Figure 1 from Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies
Figure 1 from Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies Open
A and B, Representative micrographs of HER2 IHC staining in prostate cancer (A) and urothelial cancer (B) autopsy specimens. C, Number of patients with at least one tumor with the indicated HER2 IHC score…
View article: Supplementary Table 1 from Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies
Supplementary Table 1 from Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies Open
Prostate cancer cohort supplemental table
View article: Figure 2 from Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies
Figure 2 from Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies Open
A and B, Mosaic plots indicating the relationship between ERBB2 genomic status as assessed by unadjusted copy number and HER2 IHC in (A) prostate and (B) urothelial cancers. C and D, Box plots indi…
View article: Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies
Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies Open
HER2 is an oncogenic driver in multiple cancers and a predictive biomarker for HER2-targeted therapies. Although HER2-directed therapies like fam-trastuzumab deruxtecan are approved for HER2-positive breast and other solid tumors, the land…
View article: Evaluating the Therapeutic Role of Lymph Node Dissection in Variant Subtype Bladder Cancer
Evaluating the Therapeutic Role of Lymph Node Dissection in Variant Subtype Bladder Cancer Open
Background: The importance of lymph node dissection (LND) at the time of radical cystectomy for urothelial carcinoma (UC) is widely accepted despite known risks. The therapeutic benefits of LND for variant subtype bladder cancer (VBC), a h…
View article: Supplementary Information from Prostate Cancer Risk Stratification via Nondestructive 3D Pathology with Deep Learning–Assisted Gland Analysis
Supplementary Information from Prostate Cancer Risk Stratification via Nondestructive 3D Pathology with Deep Learning–Assisted Gland Analysis Open
Supplementary methods, notes, figures, tables, video captions, and references
View article: Supplementary Information from Prostate Cancer Risk Stratification via Nondestructive 3D Pathology with Deep Learning–Assisted Gland Analysis
Supplementary Information from Prostate Cancer Risk Stratification via Nondestructive 3D Pathology with Deep Learning–Assisted Gland Analysis Open
Supplementary methods, notes, figures, tables, video captions, and references
View article: Reduced adipose tissue with limited loss of lean mass after weight loss: results from the Prostate Cancer Active Lifestyle Study
Reduced adipose tissue with limited loss of lean mass after weight loss: results from the Prostate Cancer Active Lifestyle Study Open
Adiposity reduction has cancer-specific and overall health benefits for patients with overweight or obesity. The indiscriminate loss of lean mass accompanying weight loss, however, remains a concern for older patients with cancer. Body com…
View article: Supplementary Information from Prostate Cancer Risk Stratification via Nondestructive 3D Pathology with Deep Learning–Assisted Gland Analysis
Supplementary Information from Prostate Cancer Risk Stratification via Nondestructive 3D Pathology with Deep Learning–Assisted Gland Analysis Open
Supplementary methods, notes, figures, tables, video captions, and references
View article: Supplementary Information from Prostate Cancer Risk Stratification via Nondestructive 3D Pathology with Deep Learning–Assisted Gland Analysis
Supplementary Information from Prostate Cancer Risk Stratification via Nondestructive 3D Pathology with Deep Learning–Assisted Gland Analysis Open
Supplementary methods, notes, figures, tables, video captions, and references
View article: Molecular Subtyping for Predicting Pathological Upstaging and Survival Outcomes in Clinically Organ-confined Bladder Cancer Patients Undergoing Radical Cystectomy
Molecular Subtyping for Predicting Pathological Upstaging and Survival Outcomes in Clinically Organ-confined Bladder Cancer Patients Undergoing Radical Cystectomy Open
View article: Supplementary Information from Prostate Cancer Risk Stratification via Nondestructive 3D Pathology with Deep Learning–Assisted Gland Analysis
Supplementary Information from Prostate Cancer Risk Stratification via Nondestructive 3D Pathology with Deep Learning–Assisted Gland Analysis Open
Supplementary methods, notes, figures, tables, video captions, and references